ValiRx (LON:VAL – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported GBX (0.09) earnings per share for the quarter, Digital Look Earnings reports. ValiRx had a negative net margin of 7,115.36% and a negative return on equity of 70.79%.
ValiRx Stock Performance
LON:VAL opened at GBX 0.14 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.27 and a current ratio of 4.62. The stock has a market capitalization of £1.78 million, a PE ratio of -0.25 and a beta of 0.59. ValiRx has a fifty-two week low of GBX 0.13 and a fifty-two week high of GBX 0.75. The company has a fifty day moving average of GBX 0.16 and a two-hundred day moving average of GBX 0.22.
About ValiRx
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Featured Stories
- Five stocks we like better than ValiRx
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
